BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
BillionToOne (BLLN) plans to release its third-quarter 2026 financial results after market close on November 4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BillionToOne (BLLN) plans to release its third-quarter 2026 financial results after market close on November 4, 2026.
The quarter ended September 30, 2026. A conference call to discuss the results will begin that day at 1:30pm Pacific Time / 4:30pm Eastern Time. A live and archived webcast will be available on the Events page of the company’s investor relations website.
Key Figures
- Financial results release
- November 4, 2026
- Third quarter 2026; after market close
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested listeners will be available on the “Events” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/.
About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.
Investor Contact
ir@billiontoone.com
Media Contact
billiontoone@moxiegrouppr.com
